Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy

S L Walmsley; D V Kelly; A L Tseng; A Humar; P R Harrigan

doi:10.1097/00002030-200108170-00019

Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy

AIDS. 2001 Aug 17;15(12):1581-4. doi: 10.1097/00002030-200108170-00019.

Authors

S L Walmsley¹, D V Kelly, A L Tseng, A Humar, P R Harrigan

Affiliation

¹ Toronto General Hospital Immunodeficiency Clinic, University Health Network, University of Toronto, Ontario, Canada.

PMID: 11504994
DOI: 10.1097/00002030-200108170-00019

Abstract

In a retrospective cohort study of salvage antiretroviral combination therapy including efavirenz, 60% of 51 patients were able to suppress HIV RNA by at least 1 log10 or to less than 50 copies/ml. A lack of the previous use of non-nucleoside reverse transcriptase inhibitors was the only factor predictive of response on multivariate analysis. No patient with a viral isolate with an increased IC50 to efavirenz by virtual phenotype had a virological response

MeSH terms

Adult
Alkynes
Anti-HIV Agents / therapeutic use*
Benzoxazines
Cyclopropanes
Drug Therapy, Combination
HIV Infections / drug therapy
HIV Infections / virology*
HIV-1 / drug effects
HIV-1 / isolation & purification*
Humans
Male
Oxazines / therapeutic use*
RNA, Viral / blood*
Reverse Transcriptase Inhibitors / therapeutic use*
Salvage Therapy
Treatment Outcome

Substances

Alkynes
Anti-HIV Agents
Benzoxazines
Cyclopropanes
Oxazines
RNA, Viral
Reverse Transcriptase Inhibitors
efavirenz